CN110484614A - Application of the inhibitor of LncRNA XLOC_057528 in the drug that preparation promotes angiogenesis - Google Patents
Application of the inhibitor of LncRNA XLOC_057528 in the drug that preparation promotes angiogenesis Download PDFInfo
- Publication number
- CN110484614A CN110484614A CN201910656142.6A CN201910656142A CN110484614A CN 110484614 A CN110484614 A CN 110484614A CN 201910656142 A CN201910656142 A CN 201910656142A CN 110484614 A CN110484614 A CN 110484614A
- Authority
- CN
- China
- Prior art keywords
- lncrna
- xloc
- lncrna xloc
- human umbilical
- umbilical vein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of the inhibitor of lncRNA XLOC_057528 in the drug that preparation promotes angiogenesis.Confirm that it can influence the expression of p53 gene and albumen in Human umbilical vein endothelial cells by overexpression and silencing lncRNA XLOC_057528, it also demonstrates that it participates in promoting cell proliferation of human umbilical vein, inhibits Apoptosis of Human Umbilical Vein Endothelial, Human umbilical vein endothelial cells tubule is inhibited to be formed simultaneously, further illustrates that lncRNA XLOC_057528 may participate in inhibiting the angiogenesis after myocardial infarction.Therefore, the inhibitor of lncRNA XLOC_057528 can be used for preparing the drug for promoting angiogenesis, specifically, the inhibitor of lncRNA XLOC_057528 can be used for preparing the drug of angiogenesis after promotion myocardial infarction.
Description
Technical field
The invention belongs to cell engineerings and gene engineering technology field, and in particular to a kind of long-chain non-coding RNA XLOC_
Application of the inhibitor of 057528 (lncRNA XLOC_057528) in the drug that preparation promotes angiogenesis.
Background technique
Myocardial infarction (Myocardial Infarction, MI) is a kind of cardiovascular disease for seriously endangering human health,
The disease is based on coronary atherosclerosis, the clottage coronary artery lumen of formation, since long-time ischemic is finally led
Myocardial necrosis is caused, referred to as " number one killer of human health ".
Angiogenesis is referred to from the new blood vessel that vein develops after existing capillary or capillary, mainly
The blood vessel of perfect in shape and function is formed by way of gemmation, main includes proliferation, budding and the migration of endothelial cell.Impaired
In heart, effective vascular remodeling can allow focal zone to obtain to restore to a certain extent, and vascular endothelial cell is after adult cardiac damage
Angiogenesis in play an important role.
Long-chain non-coding RNA (Long Non-coding RNA, lncRNA) is the non-coding that a kind of length is more than 200nt
RNA, most of lncRNA do not have encoding histone ability.More and more researches show that lncRNA can be used as important adjusting
The factor participates in the generation and/or development of the various diseases including MI, rises in cardiovascular physiology and pathology
To vital effect.Many document report lncRNA are in tumor disease by adjusting Human umbilical vein endothelial cells in recent years
(HUVECs) to influence angiogenesis, and the angiogenesis after MI is rarely reported.
Summary of the invention
The object of the present invention is to provide a kind of long-chain non-coding RNA XLOC_057528 (lncRNA XLOC_057528)
Application of the inhibitor in the drug that preparation promotes angiogenesis.
The present invention using lncRNA XLOC_057528 as research object, use molecular cytobiology technique study its
Application after myocardial infarction in angiogenesis confirms lncRNA XLOC_057528 in Human umbilical vein endothelial cells for the first time
Using, by overexpression and silencing lncRNA XLOC_057528 confirm that it can influence the mRNA of target gene p53 and albumen exists
Expression in Human umbilical vein endothelial cells, while also demonstrating that it participates in promoting cell proliferation of human umbilical vein, inhibits people's navel quiet
Arteries and veins endothelial cell apoptosis inhibits Human umbilical vein endothelial cells tubule to be formed, and further illustrates that lncRNA XLOC_057528 may
It participates in inhibiting the angiogenesis after myocardial infarction.Therefore, the inhibitor of lncRNA XLOC_057528 can be applied to preparation promotion
The drug of angiogenesis is particularly applicable to the drug that preparation promotes angiogenesis after myocardial infarction.
The nucleotide sequence of the lncRNA XLOC_057528 is as shown in SEQ ID NO.1.
The inhibitor of the lncRNA XLOC_057528 is the siRNA or lncRNA of lncRNA XLOC_057528
The rna interference vector of XLOC_057528.
The present invention also provides a kind of drug for promoting angiogenesis, which contains a effective amount of lncRNA XLOC_
057528 inhibitor.It is preferred that the drug of the promotion angiogenesis is the drug of angiogenesis after promoting myocardial infarction.
The present invention changes table of the lncRNA XLOC_057528 in Human umbilical vein endothelial cells by technique for gene engineering
Up to amount, it was demonstrated that: in vitro under environment, the mRNA and albumen that lncRNA XLOC_057528 promotes target gene p53 are in endothelial cell
In expression；LncRNA XLOC_057528 promotes the proliferation of Human umbilical vein endothelial cells, inhibits Human umbilical vein endothelial cells
Apoptosis；LncRNA XLOC_057528 inhibits the tubule of Human umbilical vein endothelial cells to be formed.
Specific verification test and result are as follows:
1, the present invention is detected by qRT-PCR method, and lncRNA XLOC_ is overexpressed in Human umbilical vein endothelial cells
After 057528, the expression quantity of p53mRNA increases (P < 0.01) compared with control group (pcDNA3.1 (-)), silencing lncRNA
After XLOC_057528, the expression quantity of p53mRNA reduces (P < 0.01) (Fig. 1) compared with control group (NC).
2, the present invention is detected by Western Blot method, and lncRNA is overexpressed in Human umbilical vein endothelial cells
After XLOC_057528, the expression quantity of p53 albumen increases (P < 0.05) compared with control group (pcDNA3.1 (-)), silencing lncRNA
After XLOC_057528, the expression quantity of p53 albumen reduces (P < 0.01) (Fig. 2) compared with control group (NC).
3, the present invention is detected by EdU method, and lncRNA XLOC_057528 is overexpressed in Human umbilical vein endothelial cells
Afterwards, the proliferation rate of Human umbilical vein endothelial cells increases (P < 0.01) (Fig. 3) compared with control group (pcDNA3.1 (-)), silencing
After lncRNA XLOC_057528, the proliferation rate of Human umbilical vein endothelial cells reduces (P < 0.05) (figure compared with control group (NC)
4)。
4, the present invention is detected by Annexin V-FITC/PI technology, is overexpressed in Human umbilical vein endothelial cells
After lncRNA XLOC_057528, compared with control group (pcDNA3.1 (-)) Human umbilical vein endothelial cells apoptosis rate reduce (P <
0.01) (Fig. 5), after silencing lncRNA XLOC_057528, the apoptosis rate of Human umbilical vein endothelial cells compared with control group (NC)
It increases (P < 0.01) (Fig. 6).
5, the present invention is detected by Matrigel matrigel method, and lncRNA is overexpressed in Human umbilical vein endothelial cells
After XLOC_057528, compared with control group (Blank) Human umbilical vein endothelial cells at pipe number reduce (P < 0.01) (Fig. 7), sink
After silent lncRNA XLOC_057528, compared with control group (Blank) the increasing at pipe number of Human umbilical vein endothelial cells (P <
0.01) (Fig. 8).
The invention has the benefit that
It is horizontal in gene and two, albumen that the present invention has detected p53 after overexpression/silencing lncRNA XLOC_057528
Expression quantity, at the same have detected its in the proliferation of Human umbilical vein endothelial cells, apoptosis, at pipe situation, be it in angiogenesis
Molecule mechanism and mechanism of action lay the foundation.Meanwhile the XLOC_057528 of lncRNA as the result is shown of the invention promotes p53 gene
And expression of the albumen in endothelial cell, and participate in promoting the proliferation of Human umbilical vein endothelial cells, inhibit human umblilical vein endothelial thin
The apoptosis of born of the same parents inhibits Human umbilical vein endothelial cells tubule to be formed, and further illustrates that lncRNA XLOC_057528 may be to infarct
Angiogenesis afterwards is inhibited, this for research prevention and treatment myocardial infarction novel targets and new strategy provide theoretical foundation and
Clinical Basis.The inhibitor of lncRNA XLOC_057528 can be used for preparing the drug for promoting angiogenesis, can be especially useful for
Preparation promotes the drug of angiogenesis after myocardial infarction.
Detailed description of the invention
Fig. 1 is the result figure of p53 gene expression after qRT-PCR method detection overexpression/silencing lncRNA XLOC_057528.
Wherein, pcDNA3.1 (-)-lncRNA XLOC_057528 indicates overexpression lncRNA XLOC_057528；PcDNA3.1 (-) is
Control group；LncRNA XLOC_057528Silencer indicates silencing lncRNA XLOC_057528；NC is control group.
Fig. 2 is the knot of p53 protein expression after Western Blot method detection overexpression/silencing lncRNA XLOC_057528
Fruit figure.Wherein, pcDNA3.1 (-)-lncRNA XLOC_057528 indicates overexpression lncRNA XLOC_057528；pcDNA3.1
(-) is control group；LncRNA XLOC_057528Silencer indicates silencing lncRNA XLOC_057528；NC is control group.
Fig. 3 is the result figure of cell proliferation of human umbilical vein after EdU method detection overexpression lncRNA XLOC_057528.
Wherein, pcDNA3.1 (-)-lncRNA XLOC_057528 indicates overexpression lncRNA XLOC_057528；PcDNA3.1 (-) is
Control group.
Fig. 4 is the result figure of cell proliferation of human umbilical vein after EdU method detection silencing lncRNA XLOC_057528.Its
In, lncRNA XLOC_057528Silencer indicates silencing lncRNA XLOC_057528；NC is control group.
Fig. 5 is that Human umbilical vein endothelial cells are withered after the detection of Annexin V-FITC method overexpresses lncRNA XLOC_057528
The result figure died.Wherein, pcDNA3.1 (-)-lncRNA XLOC_057528 indicates overexpression lncRNA XLOC_057528；
PcDNA3.1 (-) is control group.
Fig. 6 is Apoptosis of Human Umbilical Vein Endothelial after Annexin V-FITC method detection silencing lncRNA XLOC_057528
Result figure.Wherein, lncRNA XLOC_057528Silencer indicates silencing lncRNA XLOC_057528；NC is control
Group.
Fig. 7 is that Human umbilical vein endothelial cells are small after the detection of Matrigel matrigel method overexpresses lncRNA XLOC_057528
The result figure that pipe is formed.Wherein, pcDNA3.1 (-)-lncRNA XLOC_057528 indicates overexpression lncRNA XLOC_
057528；Blank is control group.
Fig. 8 is Human umbilical vein endothelial cells tubule after Matrigel matrigel method detection silencing lncRNA XLOC_057528
The result figure of formation.Wherein, lncRNA XLOC_057528Silencer indicates silencing lncRNA XLOC_057528；Blank
For control group.
Specific embodiment
The following examples are further illustrations of the invention, rather than limiting the invention.
LncRNA XLOC_057528 Silencer in following embodiments is with silencing lncRNA XLOC_057528
Function, synthesized by Guangzhou Ribo Bio Co., Ltd.；LncRNA XLOC_057528 Silencer NC does not have
The function of silencing lncRNA XLOC_057528 is the control of lncRNA XLOC_057528 Silencer, sharp rich by Guangzhou
Biotechnology Co., Ltd provides.
Embodiment 1
1, gene overexpression vector is constructed
LncRNA XLOC_057528 relevant to heart infarction is filtered out from difference lncRNA as research object.DNAMAN
Software analysis finds lncRNA XLOC_057528 full length gene sequence without two kinds of digestion with restriction enzyme of Kpn I and Nhe I
Site, and there are Kpn I and Nhe I restriction enzyme sites for pcDNA3.1 (-) carrier (being purchased from BioMed company, article No. CL408-01).
5.0 software design full length gene primer of primer premier, upstream and downstream primer add Kpn I and Nhe I digestion position respectively
Point sequence.Using Human umbilical vein endothelial cells cDNA as template, (target fragment of amplification is lncRNA to PCR amplification target fragment
XLOC_057528 sequence, nucleotide sequence is as shown in SEQ ID NO.1), purified recycling, double digestion, connection pcDNA3.1
Extracting endotoxin-free plasmid (endotoxin-free plasmid Mini Kit purchase after (-) carrier, conversion, screening, sequencing identification are correct
From Magen company), pcDNA3.1 (-)-lncRNA XLOC_057528 is named as (containing lncRNA XLOC_057528 sequence
Column).
2, the culture of Human umbilical vein endothelial cells
(1) endothelial cell is taken out from liquid nitrogen container, is put into 37 DEG C of water-baths and is thawed.
(2) prepare ECM complete medium: 93% ECM+5% FBS+1% ECGS+1% is dual anti-.
(3) appropriate complete medium is added in the cell to have thawed, and 1000rpm room temperature is centrifuged 5min.
(4) it discards supernatant, appropriate PBS buffer solution cleaning cell is added, 1000rpm room temperature is centrifuged 5min.
(5) it discards supernatant, cell is resuspended with complete medium, is inoculated in 75mL culture bottle；37 DEG C are placed in, 5% CO2Training
Support stationary culture in case.
Described is dual anti-for penicillin and streptomysin.
3, cell RNA extracting and reverse transcription
Cell total rna is extracted referring to Takara company's T RIzol operational manual, specific steps are as follows:
(1) culture Human umbilical vein endothelial cells abandon culture medium, PBS cleans cell twice, according to cell concentration to proper density
1000 μ L TRIzol are added, and blow and beat repeatedly several times, are allowed to sufficiently crack.
(2) lysate is transferred to new 1.5mL without in RNA enzyme centrifuge tube, ice, which incubates 5min, keeps nucleoprotein complex complete
Separation.
(3) 200 μ L chloroforms are added, acutely shake 15s, ice incubates 5min, and 4 DEG C of 11000rpm are centrifuged 15min, it is seen that mixing
Object is divided into three layers, and RNA is located in upper strata aqueous phase.
(4) upper strata aqueous phase new 1.5mL is transferred to incubate without the mixing of 500 μ L isopropanols, ice in RNA enzyme centrifuge tube, is added
10min, 4 DEG C of 1100rpm are centrifuged 10min.
(5) supernatant is removed, is carefully precipitated with 75% ethanol washing, 4 DEG C of 7500rpm are centrifuged 3min.
(6) supernatant, dry RNA to wet shape are abandoned, appropriate DEPC water dissolves RNA precipitate.
PrimeScript of the mRNA reverse transcription referring to TaKaRa companyTM RT Master Mix(Perfect Real
Time) cDNA reverse transcription reagent box carries out.
4, the inoculation and transfection of Human umbilical vein endothelial cells
(1) when Human umbilical vein endothelial cells convergence degree reaches 90%~95%, culture medium is abandoned, PBS is cleaned cell 2 times.
(2) appropriate trypsin digestion is digested wait digest that equivalent complete medium is added immediately completely and terminates.
(3) PBS is cleaned 2 times, and period 1000rpm room temperature is centrifuged 5min.
(4) cell precipitation is gently resuspended with complete medium, uniformly assigns in each hole, supplement body with complete medium
Product, gently shakes up, puts in incubator and cultivate.
(5) next day observes endothelial cell state, can transfect when cell confluency degree is up to 70%~90%.
(6) transfection method is by Invitrogen company3000 kit specifications carry out；It is divided into 4
Group, respectively overexpression lncRNA XLOC_057528 group (transfection pcDNA3.1 (-)-lncRNA XLOC_057528), control
Group (transfection pcDNA3.1 (-)), silencing lncRNA XLOC_057528 group (transfection lncRNA XLOC_057528 Silencer,
The lncRNA XLOC_057528 Silencer has the function of silencing lncRNA XLOC_057528, is by 6 sequences
Column composition, 3 ASO sequences and 3 siRNA sequences) and control group NC (transfection lncRNA XLOC_057528 Silencer
NC, the lncRNA XLOC_057528 Silencer NC do not have the function of silencing lncRNA XLOC_057528,
It is made of 2 sequences, 1 ASO sequence and 1 siRNA sequence), 3 repetitions of every group of setting.
(7) cell after transfecting is placed in 37 DEG C, 5%CO2Continue to cultivate in incubator.
(8) according to experiment purpose, 24~48h collects cell after transfection.
5, qRT-PCR detects p53 gene expression after overexpression/silencing lncRNA XLOC_057528
The detection of gene relative expression quantity uses Maxima SYBR Green qPCR Master Mix (2 in the present invention
×) kit (Thermo Scientific company) progress.Experimental result, which uses, compares containing for Ct value method test sample gene
Amount, specific formula for calculation are as follows:
Gene relative expression quantity=2{ < ﹙ experimental group target gene Ct Zhi ﹚-﹙ experimental group reference gene Ct Zhi ﹚ >-< ﹙ control group target gene Ct Zhi ﹚-﹙ control group reference gene Ct Zhi ﹚ > }
Wherein β-Actin is as reference gene, qRT-PCR primer used in the present invention are as follows:
QRT-PCR-p53Forward:5 '-CAGCCTGGGCACAACAATTC-3 '；
Reverse:5 '-GTGCTCCTCGTGCTTACACT-3 '；
QRT-PCR- β-Actin Forward:5 '-TCCCTGGAGAAGAGCTACGA-3 '；
Reverse:5 '-AGCACTGTGTTGGCGTACAG-3 '.
The present invention synthesizes lncRNA XLOC_057528 overexpression vector (pcDNA3.1 by technique for gene engineering external source
(-)-lncRNA XLOC_057528) and lncRNA function inhibitio silencing agent (lncRNA XLOC_
057528Silencer), it and is transfected to Human umbilical vein endothelial cells, carries out qRT-PCR afterwards for 24 hours, to p53 mRNA table
It is detected up to situation.Testing result shows after overexpressing lncRNA XLOC_057528, with control group (pcDNA3.1 (-))
Expression quantity compared to p53 gene increases (P < 0.01), after silencing lncRNA XLOC_057528, the p53 compared with control group (NC)
The expression quantity of gene reduces (P < 0.01) (Fig. 1).
6, Western Blot detects p53 protein expression after overexpression/silencing lncRNA XLOC_057528
(1) extraction of total protein of cell
A) 48h after cell transfecting is cleaned cell 3 times with PBS, and 100~200 μ L protein lysates are added and 10 μ L concentration are
The cell of cracking is transferred in 1.5mL EP pipe by the PMSF of 100mM.
B) cell is shaken, until cracking completely.
C) 12000rpm, 4 DEG C of centrifugation 15min, takes supernatant into new 1.5mL EP pipe, cryo-conservation.
(2) BCA method measures protein concentration
A) preparation of protein standard substance: it is 0.5mg/mL's that the standard protein mother liquor of 2mg/mL, which is diluted to concentration, with PBS
Working solution, cryo-conservation.
B) configuration of BCA working solution: BCA working solution is configured according to each sample 200uL working solution.
C) it is sequentially added in 96 orifice plate standard sample wells by 0,2,4,8,16 μ L of standard items, PBS complements to 20 μ L.
D) every hole adds the diluted protein sample (protein sample PBS=2:18) of 20 μ L in 96 orifice plate gauge orifices.
E) every hole adds the BCA working solution of 200 μ L, after mixing, 37 DEG C of incubation 30min.
F) the OD value of each porin of A570nm is measured.The total protein of extraction, addition 5 × SDS albumen sample-loading buffer (press 1:
4 ratio), heat denatured, -80 DEG C save backup.
(3) prepared by PAGE gel
A) it is dried after glass plate cleans up stand-by.
B) it is fixed on gum-making rack after glass plate alignment, bottom is sealed with rubber strip.
C) 10% separation gel is configured, is poured into after mixing from glass plate bottom, isopropanol is added, is stood solid to gelling.
D) isopropanol is abandoned, and is exhausted with filter paper, configuration 5%, which is concentrated glue and pours into rapidly, fills up remaining gap.
E) it is inserted into comb, after being gelled admittedly, starts sample-adding and carries out electrophoresis.
(4) albumen loading: protein sample is added in loading wells with pipettor.
(5) gel electrophoresis: the voltage of bubble concentration glue is 70V, time 30min；The voltage of separation gel is run in 120V.
(6) transferring film
A) formaldehyde impregnates pvdf membrane 5min, and clear water is reinstated transferring film liquid with absorbent filter paper one after rinsing and impregnated.
B) successively folded according to absorbent filter paper (4)-sequence of gel-pvdf membrane-absorbent filter paper (4) since anode
It puts, closes cathode.It is fitted into electrophoresis tank.
C) During migration carries out on ice, constant current 300mA, selects the transferring film time according to destination protein difference.
(7) Protein Detection and interpretation of result
A) film is put into 1 × TBST and is rinsed, close 2h at room temperature with 5% skimmed milk power.
B) primary antibody is incubated for: abandoning confining liquid, 1 × TBST washes film, antibody needed for being diluted with antibody diluent, 4 DEG C of overnight incubations.
C) primary antibody is recycled, 1 × TBST washes film.
D) secondary antibody is incubated for: being abandoned TBST, is incubated for secondary antibody, antibody is diluted to required concentration with antibody diluent, is incubated at room temperature
2h.Secondary antibody is abandoned, 1 × TBST washes film.
E) it develops the color: being detected with ECL chemoluminescence method, exposed with Bio-Rad exposure system and acquire picture.
F) measurement of electrophoretic band gray value is carried out using Image J.
The present invention synthesizes lncRNA XLOC_057528 overexpression vector (pcDNA3.1 by technique for gene engineering external source
(-)-lncRNA XLOC_057528) and lncRNA function inhibitio silencing agent (lncRNA XLOC_
057528Silencer), it and is transfected to Human umbilical vein endothelial cells, 48h carries out Wetern Blot, to p53 albumen table
It is detected up to situation.Testing result shows after overexpressing lncRNA XLOC_057528, with control group (pcDNA3.1 (-))
Expression quantity compared to p53 albumen increases (P < 0.05), after silencing lncRNA XLOC_057528, the p53 compared with control group (NC)
The expression quantity of albumen reduces (P < 0.01) (Fig. 2).
7, cell proliferation of human umbilical vein detects
The Cell- of EdU method detection cell proliferation experiment reference Guangzhou Rui Bo Biotechnology Co., Ltd in the present invention
LightTMEdU Apollo 567In vitro Kit is carried out.Specific step is as follows (by taking 48 orifice plates as an example):
(1) the dilution proportion Edu solution that 1000:1 is pressed with complete medium, prepares appropriate Edu culture medium.
(2) every 200 μ L Edu culture medium of hole is incubated for 2h, abandons culture medium.
(3) PBS is cleaned cell 2 times, each 5min.
(4) every 100 μ L cell fixer of hole (using diluted 80% acetone of PBS) incubation at room temperature 30min, abandons fixer.
(5) every 200 μ L PBS of hole, decolorization swinging table clean 5min, abandon PBS.
(6) 1 × Apollo staining reaction liquid of every 200 μ L of hole is protected from light, room temperature, decolorization swinging table are incubated for 20min, abandoning dyeing
Reaction solution.
(7) every 200 μ L bleeding agent of hole (PBS containing 0.5% Triton X) decolorization swinging table cleans 2 times, each 10min, abandons
Bleeding agent, PBS clean 5min.
(8) the dilution proportion reagent F that 100:1 is pressed with deionized water, prepares appropriate 1 × Hoechst3342 reaction solution, is protected from light
It saves.
(9) every 200 μ L 1 × Hoechst3342 reaction solution of hole is protected from light, room temperature, decolorization swinging table are incubated for 20min, abandoning dyeing
Reaction solution.
(10) every 200 μ L PBS of hole is cleaned 2 times, and every 200 μ L PBS of hole saves stand-by after the completion of cleaning.
(11) after the completion of dyeing, photo acquisition is carried out with fluorescence microscope.
The present invention synthesizes lncRNA XLOC_057528 overexpression vector (pcDNA3.1 by technique for gene engineering external source
(-)-lncRNA XLOC_057528) and lncRNA function inhibitio silencing agent (lncRNA XLOC_
057528Silencer), it and is transfected to Human umbilical vein endothelial cells, it is rear referring to EdU kit specification for 24 hours, internally
The proliferative conditions of chrotoplast are detected.Testing result shows after overexpressing lncRNA XLOC_057528, with control group
(pcDNA3.1 (-)) increases (P < 0.01) (Fig. 3) compared to the proliferation rate of endothelial cell, after silencing lncRNA XLOC_057528,
The proliferation rate of endothelial cell reduces (P < 0.05) (Fig. 4) compared with control group (NC).
8, Apoptosis of Human Umbilical Vein Endothelial detects
The present invention detects Apoptosis using Annexin V-FITC/PI technology, has referring to Guangzhou cortex biotechnology
Limit company FITC Annexin V Apoptosis Detection Kit with PI kit specification, concrete operation step
It is as follows:
(1) tissue culture plate is taken out, at room temperature with PBS gently rinse culture plate inner cell, abandons PBS；
(2) appropriate trypsin digestion is put into incubator 3min or so, and the termination of equivalent complete medium is added later and disappears
Change；
(3) 1000rpm is centrifuged 5min and collects cell, abandons supernatant, is cleaned cell 2 times with pre-cooling PBS.Adjust every solencyte number
It is 0.2~1.0 × 106It is a, 500 μ L 1 × Annexin V Buffer are added, cell is resuspended.
(4) 5 μ L Annexin V-FITC and 5 μ L propidium iodide stain liquid are added in every pipe sample, mix gently, room temperature (25
DEG C) it is protected from light 15min.
(5) it is analyzed immediately with flow cytomery after having reacted.
The present invention synthesizes lncRNA XLOC_057528 overexpression vector (pcDNA3.1 by technique for gene engineering external source
(-)-lncRNA XLOC_057528) and lncRNA function inhibitio silencing agent (lncRNA XLOC_
057528Silencer), it and is transfected to Human umbilical vein endothelial cells, referring to FITC Annexin V after 48h
Apoptosis Detection Kit with PI specification, the apoptosis situation of Human Umbilical Vein Endothelial Cells are detected.Testing result table
Bright, after overexpressing lncRNA XLOC_057528, the apoptosis rate of endothelial cell reduces (P compared with control group (pcDNA3.1 (-))
< 0.01) (Fig. 5), after silencing lncRNA XLOC_057528, compared with control group (NC) apoptosis rate of endothelial cell increase (P <
0.01) (Fig. 6).
9, Human umbilical vein endothelial cells are detected at pipe
(1) Matrigel matrigel melts in 4 DEG C of refrigerator overnights, and 48 orifice plates and pipette tips are stayed overnight in 4 DEG C of refrigerator pre-coolings.
(2) operate on ice: every 100 μ L matrigel of hole adds to 48 orifice plates, it is ensured that bottom hole is completely covered in glue, avoids adition process
Middle generation bubble.
(3) 37 DEG C of incubation 60min.
(4) vitellophag, it is ensured that there are 20,000 to 30,000 cells in every hole.
(5) 37 DEG C of 2~8h of incubation can complete to take pictures in fluorescence microscopy microscopic observation, 10h at any time.
The present invention synthesizes lncRNA XLOC_057528 overexpression vector (pcDNA3.1 by technique for gene engineering external source
(-)-lncRNA XLOC_057528) and lncRNA function inhibitio silencing agent (lncRNA XLOC_
057528Silencer), it and is transfected to Human umbilical vein endothelial cells, it is rear referring to Matrigel matrigel method explanation for 24 hours
Book, Human Umbilical Vein Endothelial Cells are detected at pipe situation.Testing result do not show after overexpressing lncRNA XLOC_057528, and not
Endothelial cell (blank control, Blank) by any processing reduces (P < 0.01) (Fig. 7) at pipe number compared to endothelial cell,
It is thin compared to endothelium with the endothelial cell (blank control, Blank) without any processing after silencing lncRNA XLOC_057528
Born of the same parents' increases (P < 0.01) (Fig. 8) at pipe number.
The present invention passes through overexpression and silencing lncRNA XLOC_ using lncRNA XLOC_057528 as research object
057528 confirms that it can influence the expression of p53 gene and albumen in Human umbilical vein endothelial cells, while also demonstrating its participation
Promote cell proliferation of human umbilical vein, inhibits Apoptosis of Human Umbilical Vein Endothelial, inhibits Human umbilical vein endothelial cells small tubular
At further explanation lncRNA XLOC_057528 may participate in inhibiting the angiogenesis after myocardial infarction.Therefore, lncRNA
The inhibitor of XLOC_057528 can be used for preparing the drug for promoting angiogenesis, specifically, lncRNA XLOC_057528 inhibits
Agent can be used for preparing the drug of angiogenesis after promotion myocardial infarction.
The above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
Limitation of the invention, protection scope of the present invention should be defined by the scope defined by the claims..For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these change
It also should be regarded as protection scope of the present invention into retouching.
Sequence table
<110>Experimental Animals Supervising Station, Guangdong Prov.
Agricultural University Of South China
<120>application of the inhibitor of LncRNA XLOC_057528 in the drug that preparation promotes angiogenesis
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2085
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
tttcacttct ctttctactc aggctggact cagagggagc agcagtttca gcttctcatt 60
cttggaggag atggcctgct accagtcgct tggccaaacc catcatgtga gtagcgttgc 120
tttacctgtt ccccggggga ctgagggaca gccagaggga acctgtccct cccagcacaa 180
ggggtaggtg gcacattctg cacctgccag ccctcccagt gtgtcgggag atgccgtgaa 240
ggggttgcca cctccctctg atatcctttc tgcatccttt ctggatgcaa gtggcttcat 300
gtccttgcta ttccatacct gcctgaagcc tcagtttctt catatttaaa aagcctagac 360
ctggagttcc cattgtgact cagcaggtta agaacctgac tggtatccat gaggatgcag 420
gttcgatccc tggcctcact caatgggtta aggatccggc gttgccgtga gctgtggtgt 480
atgttgcaga tgcagcttgc atcctgtgtt gctgtggctg tggtatagga tggcggcagc 540
agctttgatt tggccccgag tctgggaact cacatatgcc tcagatgtgg cccttaaata 600
gacaaaaaca aaacaaaaca aaacatcgat ttctccactg ggcatcctct gtgtaaccac 660
attaaaaaat cctccctata gattttgtcc ttgaaaagat ccagccaaag atgagaatta 720
ttttcaggtg tgctccttct ccgagtttca acagcgacaa ttagctggag atgtatggtt 780
tctccagaaa aacaggaccc ataggataca cgtatgaaga catttatttg aaggtagtgg 840
ctcacgcagt tatgggggcc gtctgatcga agctgggttt tgacattcaa agtaaaataa 900
ttcccaagtc atttatttat gaaattagct ctccttcaaa ggtaataacc atggccattt 960
tcacgtgtgg agggctaaat aacaccctct gtggtgtgat cccaaggaaa tctgcttatt 1020
cctcaaagta tctttttcag tgcacctgtc ctcgaggctg aaacgccaca gttactcctt 1080
gagcccatta taaggaaaat actctgagac tttgcgcacg gcaaggtcct gctgtaaatt 1140
tggaaaggat gtgaaggttg ttcccaggag gaggcttgag tggcgtcctt gggtggcggc 1200
tgagtggctc ccccccactt gctgagcaca ggaagtagga ggaaaaaaga agcaccaagg 1260
aaaaggcgca tgggagacaa tgaaagaaag gaggtgggca ggagagggat gccctgagga 1320
agctacgggt ctaggactgt ttgagcaaca cggaagcaca gaattttagt aacgtaacag 1380
ctggtctgag cccaaccaat ctgatctccg ctctgattac tggacgtgca ctccgccccc 1440
catccacctg gaccaatgac agtctcctgc tcctggcatg accagctcac cctggtatgc 1500
aggtcctttg atcaggggat cctctcagcc ttgggcaaac tgggatgatg agtgattgcc 1560
cccccccgcc cccaatacaa ccatcaccat ggaaacttag ggacgaattt cttttgtgag 1620
tttaccaaag gggggcattt tgcctggcca acttgagttt gggtgccagg actgagactc 1680
tcaaggccga gagccaggat gctcagtgga aatgaccact cccctgtttg gtcttctggg 1740
cagacagtgt gatttttgtg cgtcctgtta gctaattgta agtggtggga attcacgtgc 1800
aggtgctctc gtgttgggct tgtctgcata cgcttcgtaa ggaagctcag tctagcgcca 1860
agagtggctg agggtcagaa gaacctgggt tctagtctca gctcatccat tgaatttcgt 1920
gtgaccttcg gtagctgttt tttctcttct caatagcctc atctataaac tgtgatgttt 1980
tgtgttagat gttgcgttca gctccggtgt gaaccctccc tgcctgtttt ccctctagaa 2040
caaaatggaa gggcttcaga aggctgggga agacgcatgc gccac 2085
Claims (5)
- Application of the inhibitor of 1.lncRNA XLOC_057528 in the drug that preparation promotes angiogenesis, the lncRNA The nucleotide sequence of XLOC_057528 is as shown in SEQ ID NO.1.
- 2. application according to claim 1, which is characterized in that be the drug of the angiogenesis after preparation promotes myocardial infarction In application.
- 3. application according to claim 1, which is characterized in that the inhibitor of the lncRNA XLOC_057528 is The rna interference vector of the siRNA or lncRNA XLOC_057528 of lncRNA XLOC_057528.
- 4. a kind of drug for promoting angiogenesis, which is characterized in that the inhibition containing a effective amount of lncRNA XLOC_057528 Agent, the nucleotide sequence of the lncRNA XLOC_057528 is as shown in SEQ ID NO.1.
- 5. the drug according to claim 4 for promoting angiogenesis, which is characterized in that the drug is to promote cardiac muscle stalk The after death drug of angiogenesis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910656142.6A CN110484614B (en) | 2019-07-19 | 2019-07-19 | Application of LncRNA XLOC _057528 inhibitor in preparation of medicine for promoting angiogenesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910656142.6A CN110484614B (en) | 2019-07-19 | 2019-07-19 | Application of LncRNA XLOC _057528 inhibitor in preparation of medicine for promoting angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110484614A true CN110484614A (en) | 2019-11-22 |
| CN110484614B CN110484614B (en) | 2022-07-26 |
Family
ID=68547596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910656142.6A Active CN110484614B (en) | 2019-07-19 | 2019-07-19 | Application of LncRNA XLOC _057528 inhibitor in preparation of medicine for promoting angiogenesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110484614B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111286536A (en) * | 2020-04-24 | 2020-06-16 | 山东大学齐鲁医院(青岛) | Gene marker for diagnosing myocardial infarction and application thereof |
| CN112843083A (en) * | 2021-02-23 | 2021-05-28 | 青岛市中心医院 | Acute myocardial infarction treatment medicine |
| CN114958849A (en) * | 2022-05-26 | 2022-08-30 | 华南农业大学 | Application of lncRNACACF (long chain ribonucleic acid) adsorption miR-520b-3p in regulation of human umbilical vein endothelial cell cycle |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170037405A1 (en) * | 2014-04-22 | 2017-02-09 | Medizinische Hochschule Hannover | Incrnas for therapy and diagnosis of angiogenesis |
| US20170275619A1 (en) * | 2016-03-04 | 2017-09-28 | The Administrators Of The Tulane Educational Fund | Compositions and methods for treating vascular disorders |
| US20180023080A1 (en) * | 2015-02-03 | 2018-01-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction |
-
2019
- 2019-07-19 CN CN201910656142.6A patent/CN110484614B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170037405A1 (en) * | 2014-04-22 | 2017-02-09 | Medizinische Hochschule Hannover | Incrnas for therapy and diagnosis of angiogenesis |
| US20180023080A1 (en) * | 2015-02-03 | 2018-01-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Long Non-Coding RNA For The Treatment Of Endothelial Dysfunction |
| US20170275619A1 (en) * | 2016-03-04 | 2017-09-28 | The Administrators Of The Tulane Educational Fund | Compositions and methods for treating vascular disorders |
Non-Patent Citations (3)
| Title |
|---|
| HALIMULATI等: "Long noncoding RNA TCONS_00024652 regulates vascular endothelial cell proliferation and angiogenesis via microRNA-21", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| SUN等: "Long non-coding RNA H19 promotes corneal neovascularization by targeting microRNA-29c", 《BIOSCIENCE REPORTS》 * |
| ZHENG等: "lncRNA PVT1 promotes the angiogenesis of vascular endothelial cell by targeting miR-26b to activate CTGF/ANGPT2", 《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111286536A (en) * | 2020-04-24 | 2020-06-16 | 山东大学齐鲁医院(青岛) | Gene marker for diagnosing myocardial infarction and application thereof |
| CN112843083A (en) * | 2021-02-23 | 2021-05-28 | 青岛市中心医院 | Acute myocardial infarction treatment medicine |
| CN112843083B (en) * | 2021-02-23 | 2021-09-07 | 青岛市中心医院 | Acute myocardial infarction treatment medicine |
| CN114958849A (en) * | 2022-05-26 | 2022-08-30 | 华南农业大学 | Application of lncRNACACF (long chain ribonucleic acid) adsorption miR-520b-3p in regulation of human umbilical vein endothelial cell cycle |
| CN114958849B (en) * | 2022-05-26 | 2023-10-27 | 华南农业大学 | Application of lncRNACACF to miR-520b-3p adsorption in regulation of human umbilical vein endothelial cell cycle |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110484614B (en) | 2022-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110384800A (en) | Application of the LncRNA XLOC_075168 in the drug that preparation promotes angiogenesis | |
| CN110484614A (en) | Application of the inhibitor of LncRNA XLOC_057528 in the drug that preparation promotes angiogenesis | |
| CN110403954A (en) | Application of the inhibitor of LncRNA XLOC_110286 in the drug that preparation promotes angiogenesis | |
| CN110791501B (en) | Long-chain non-coding RNA and application of interference RNA thereof in treatment of atherosclerosis | |
| CN106480037A (en) | A kind of long non-coding RNA and the application in diagnosis preeclampsia and target drug treatment is prepared | |
| WO2019206341A1 (en) | Rab22a-noefs fusion gene line for diagnosis and/or treatment of osteosarcoma and application thereof | |
| CN107805663A (en) | Application of the Lnc03729 genes as biomarker in the pre- diagnostic reagent of adenocarcinoma of lung | |
| CN110373416A (en) | Application of the RBP1 gene in sow gonad granulocyte | |
| CN103966227B (en) | Coding nucleotide sequence of MG53 (mitsugumin53) protein with codon optimization, recombinant of MG 53 protein as well as application of MG 53 protein | |
| CN108004322A (en) | A kind of applications of lncRNA in adenocarcinoma of lung is diagnosed and/or treated | |
| CN114032237A (en) | Circular non-coding RNA circSTK39 and application thereof in preventing and treating atherosclerosis | |
| CN110846315B (en) | Long-chain non-coding RNA XLOC _102237 and application thereof in human umbilical vein endothelial cells | |
| CN108913695B (en) | Application of ZEB1 in human heart fibroblast | |
| Tao et al. | Small extracellular vesicles with LncRNA H19 “overload”: YAP regulation as a tendon repair therapeutic tactic | |
| CN108531544A (en) | A kind of method of miR-181b target genes screening | |
| CN102199625B (en) | Construction method for miRNA (micro Ribonucleic Acid) transgenic mouse model | |
| CN108676874B (en) | Application of circulating exosome long-chain non-coding RNA-TC0101441 as marker for diagnosing endometriosis | |
| CN115607689A (en) | Application of KLF7 gene in preparation of drug for reversing cell senescence | |
| CN110229900A (en) | Gene hsa_circ_0103520 relevant to breast cancer diagnosis and treatment and its application | |
| CN104862316A (en) | MiRNA-2400 with biological function of significantly promoting bovine preadipocyte proliferation | |
| CN105624159B (en) | A kind of siRNA and its application for people's EDIL3 gene | |
| CN110846313B (en) | Long-chain non-coding RNA XLOC _025806 and application thereof in human umbilical vein endothelial cells | |
| CN110747162B (en) | Application of small molecular compound 4-aminobiphenyl in promoting stem cell proliferation and chondrogenic differentiation | |
| Yuan et al. | miR‐212 Promotes Cardiomyocyte Hypertrophy through Regulating Transcription Factor 7 Like 2 | |
| CN104877960B (en) | MiR 2400 remarkably promotes the biological function of bovine muscle satellite cell propagation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |